# Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

> **NCT06629389** · PHASE2 · RECRUITING · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 88 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Cannabidiol 100 mg/ml
- **DRUG:** cannabidiol 300 mg/ml
- **DRUG:** Cannabidiol 400 mg/ml
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06629389
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-28
- **Primary completion:** 2025-11
- **Final completion:** 2026-11
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06629389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06629389, "Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06629389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*